The seven big pharma leaders who testified at the Senate Finance Committee hearing on drug pricing Feb. 26 largely stuck together in responding to questions, a united front that particularly stands out when looking at the executives' responses to the yes-or-no questions posed by senators.
Those types of questions could have presented a potential pitfall: a video clip of all seven admitting that yes, drug...






